A. Ettrup

发表

Serotonin 2A Receptor Agonist Binding in the Human Brain with [11C]Cimbi-36

C. Svarer, G. Knudsen, S. Lehel, 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

G. Knudsen, A. van Waarde, S. D. de Boer, 2015, Synapse.

Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain

C. Halldin, G. Knudsen, L. Farde, 2017, The international journal of neuropsychopharmacology.

Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans

C. Svarer, G. Knudsen, M. Schain, 2019, European Neuropsychopharmacology.

No change in [11C]CUMI‐101 binding to 5‐HT1A receptors after intravenous citalopram in human

C. Svarer, T. Kjaer, O. Paulson, 2012, Synapse.

Cerebral Markers of the Serotonergic System in Rat Models of Obesity and After Roux‐en‐Y Gastric Bypass

Mette E. Haahr, G. Knudsen, V. Compan, 2012, Obesity.

Evaluation of 3-Ethyl-3-(phenylpiperazinylbutyl)oxindoles as PET Ligands for the Serotonin 5-HT₇ Receptor: Synthesis, Pharmacology, Radiolabeling, and in Vivo Brain Imaging in Pigs.

P. Svenningsson, G. Knudsen, S. Lehel, 2015, Journal of medicinal chemistry.

Radiosynthesis and In Vivo Evaluation of Novel Radioligands for PET Imaging of Cerebral 5-HT7 Receptors

G. Knudsen, S. Lehel, H. D. Hansen, 2014, The Journal of Nuclear Medicine.

Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapy

G. Knudsen, S. Lehel, H. D. Hansen, 2014 .

11C-NS14492 as a Novel PET Radioligand for Imaging Cerebral α7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements

G. Knudsen, E. Nielsen, D. Peters, 2011, The Journal of Nuclear Medicine.

Synthesis and evaluation of [¹¹C]Cimbi-806 as a potential PET ligand for 5-HT₇ receptor imaging.

G. Knudsen, S. Lehel, H. D. Hansen, 2012, Bioorganic & medicinal chemistry.

Universitet Design of Infusion Schemes for Neuroreceptor Imaging

C. Svarer, O. Paulson, G. Knudsen, 2016 .

Design of Infusion Schemes for Neuroreceptor Imaging: Application to [11C]Flumazenil-PET Steady-State Study

C. Svarer, O. Paulson, G. Knudsen, 2016, BioMed Research International.

Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study

M. Fava, J. Biederman, A. Ettrup, 2019, Journal of psychopharmacology.

Radiolabelling and PET brain imaging of the α₁-adrenoceptor antagonist Lu AE43936.

G. Knudsen, H. Pedersen, B. Bang-Andersen, 2013, Nuclear medicine and biology.

11C-NS14492 as a Novel PET Radioligand for Imaging Cerebral α7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements

G. Knudsen, E. Nielsen, D. Peters, 2011, The Journal of Nuclear Medicine.

Cerebral a7 Nicotinic Acetylcholine Receptors: In Vivo Evaluation and Drug Occupancy Measurements

G. Knudsen, D. Peters, J. Mikkelsen, 2011 .

Real-world effectiveness of vortioxetine in outpatients with major depressive disorder: functioning and dose effects

M. Markopoulou, A. Ettrup, P. Panagiotidis, 2022, BMC Psychiatry.

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study

R. Cady, D. Buse, A. Ettrup, 2022, The Journal of Headache and Pain.

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab

R. Cady, A. Blumenfeld, A. Ettrup, 2022, BMC Neurology.

Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention

Carrie R. Houts, R. Lipton, R. Cady, 2022, Headache.

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

R. Cady, P. Winner, A. Ettrup, 2022, BMC Neurology.

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies

R. Cady, E. Spierings, A. Ettrup, 2021, The Journal of Headache and Pain.

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine

R. Cady, A. Ettrup, D. Kudrow, 2022, Cephalalgia : an international journal of headache.

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2

R. Cady, M. Ashina, A. Ettrup, 2022, Cephalalgia : an international journal of headache.

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.

R. Cady, P. Winner, A. Ettrup, 2021, JAMA.

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies

R. Cady, D. Dodick, P. Pozo‐Rosich, 2022, BMC Neurology.

Synthesis, radiofluorination, and preliminary evaluation of the potential 5-HT2A receptor agonists [18 F]Cimbi-92 and [18 F]Cimbi-150.

G. Knudsen, H. D. Hansen, M. Herth, 2017, Journal of labelled compounds & radiopharmaceuticals.

Synthesis and evaluation of (18)F-labeled 5-HT2A receptor agonists as PET ligands.

G. Knudsen, S. Lehel, H. D. Hansen, 2016, Nuclear medicine and biology.

Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

M. Ashina, P. Pozo‐Rosich, M. Lanteri-Minet, 2022, The Lancet Neurology.

Eptinezumab for migraine prevention in patients 50 years or older

R. Cady, C. Tassorelli, V. Martin, 2022, Acta neurologica Scandinavica.

Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study

P. Goadsby, P. Barbanti, A. Ettrup, 2022, The Journal of Headache and Pain.

Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder

Gang Wang, H. Loft, A. Ettrup, 2020, Current medical research and opinion.

Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study

J. Haro, K. Larsen, D. Saragoussi, 2019, Neuropsychiatric disease and treatment.

Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China

Lingjiang Li, Y. Fang, T. Si, 2019, Neuropsychiatric disease and treatment.

NDT_A_195505 1723..1736

Lingjiang Li, Y. Fang, T. Si, 2019 .

Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin

Claus Svarer, Gitte Moos Knudsen, Anders Ettrup, 2016, NeuroImage.

The Center for Integrated Molecular Brain Imaging (Cimbi) database

Hartwig R. Siebner, Lars Kai Hansen, Olaf B. Paulson, 2016, NeuroImage.

Synthesis, radiolabeling and in vivo evaluation of [(11)C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT(7) receptor.

G. Knudsen, E. Lacivita, M. Leopoldo, 2014, European journal of medicinal chemistry.

Blood BDNF concentrations reflect brain-tissue BDNF levels across species.

G. Knudsen, M. Rios, C. Clemmensen, 2011, The international journal of neuropsychopharmacology.

Design, synthesis, radiolabeling and in vivo evaluation of potential positron emission tomography (PET) radioligands for brain imaging of the 5-HT₇ receptor.

Anders Ettrup, Szabolcs Lehel, Matthias M Herth, 2014, Bioorganic & medicinal chemistry.

Patient Expectations and Experiences of Antidepressant Therapy for Major Depressive Disorder: A Qualitative Study

B. Baune, A. Ettrup, Bjarke Ebert, 2021, Neuropsychiatric disease and treatment.

Feasibility of simultaneous PET/MR in diet-induced atherosclerotic minipig: a pilot study for translational imaging.

A. Hansen, H. Johannesen, A. Kjær, 2014, American journal of nuclear medicine and molecular imaging.

Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study

P. Chokka, J. Proulx, A. Ettrup, 2019, CNS Spectrums.

Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain

G. Knudsen, B. Mattsson, D. Kirik, 2010, Experimental Neurology.

An approach for serotonin depletion in pigs: Effects on serotonin receptor binding

G. Knudsen, B. Kornum, P. Weikop, 2011, Synapse.

Plaque deposition dependent decrease in 5-HT2A serotonin receptor in AbetaPPswe/PS1dE9 amyloid overexpressing mice.

G. Knudsen, J. Mikkelsen, A. B. Elvang, 2010, Journal of Alzheimer's disease : JAD.

Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.

M. DelBello, R. Findling, A. Zuddas, 2022, Journal of the American Academy of Child and Adolescent Psychiatry.

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study

A. Ettrup, I. Florea, C. Baayen, 2020, International clinical psychopharmacology.

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population

Gang Wang, A. Ettrup, A. Højer, 2019, Advances in Therapy.

Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study

E. Vieta, A. Ettrup, I. Florea, 2019, International clinical psychopharmacology.

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study

S. Potkin, D. Naber, P. Hertel, 2017, PloS one.

Cognitive Performance of Göttingen Minipigs Is Affected by Diet in a Spatial Hole-Board Discrimination Test

L. Matthews, A. Ettrup, A. Klein, 2013, PloS one.

Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain

Gitte Moos Knudsen, Anders Ettrup, Christer Halldin, 2014, NeuroImage.

Preclinical Safety Assessment of the 5-HT2A Receptor Agonist PET Radioligand [11C]Cimbi-36

Claus Svarer, Gitte Moos Knudsen, Anders Ettrup, 2013, Molecular Imaging and Biology.

Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain

Anders Ettrup, Flemming L Andersen, Jonas Villadsen, 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Improvements in Workplace Productivity in Working Patients with Major Depressive Disorder: Results from the AtWoRC Study.

P. Chokka, A. Ettrup, G. Clerzius, 2019, Journal of occupational and environmental medicine.

Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies

R. Cady, A. Ettrup, Vivienne Shen, 2022, Cephalalgia Reports.

Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study

M. Ashina, P. Pozo‐Rosich, M. Lanteri-Minet, 2023, Cephalalgia : an international journal of headache.

Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers

Anders Ettrup, Nic Gillings, Matthias M. Herth, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Anxiety symptoms in working patients with major depressive disorder treated with vortioxetine: associations with clinical and treatment outcomes in the AtWoRC study

P. Chokka, A. Ettrup, G. Clerzius, 2021, Therapeutic advances in psychopharmacology.

Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET

Anders Ettrup, Nic Gillings, Gitte M. Knudsen, 2010, The Journal of Nuclear Medicine.

Direct comparison of [18F]MH.MZ and [18F]altanserin for 5‐HT2A receptor imaging with PET

Anders Ettrup, Nic Gillings, Matthias M Herth, 2013, Synapse.

Pilot study on receptor binding and serotonin sensitivity of [11C]CIMBI-36 in monkey brain

Anders Ettrup, Christer Halldin, Sjoerd J. Finnema, 2011 .

Eptinezumab improved patient‐reported outcomes and quality of life in patients with migraine and prior preventive treatment failures

P. Goadsby, P. Barbanti, A. Ettrup, 2022, European journal of neurology.

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

R. Cady, P. Winner, A. Ettrup, 2022, BMC Neurology.

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study

R. Lipton, R. Cady, P. Winner, 2022, The Journal of Headache and Pain.

Synthesis, radiolabeling and in vivo evaluation of [(11)C](R)-1-[4-[2-(4-methoxyphenyl)phenyl]piperazin-1-yl]-3-(2-pyrazinyloxy)-2-propanol, a potential PET radioligand for the 5-HT(7) receptor.

G. Knudsen, E. Lacivita, M. Leopoldo, 2014, European journal of medicinal chemistry.

Radiosynthesis and in vitro validation of (3)H-NS14492 as a novel high affinity alpha7 nicotinic receptor radioligand.

G. Knudsen, C. Donat, D. Peters, 2015, European journal of pharmacology.

Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study

P. Chokka, J. Proulx, A. Ettrup, 2019, CNS Spectrums.

Characterizing the binding of TC-5619 and encenicline on the alpha7 nicotinic acetylcholine receptor using PET imaging in the pig

G. Knudsen, S. Lehel, A. Ettrup, 2024, Frontiers in neuroimaging.